Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

Related Articles by Review for PubMed (Select 20695012)

1.

Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis.

Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P, van der Mei I.

Ann Neurol. 2010 Aug;68(2):193-203. doi: 10.1002/ana.22043.

PMID:
20695012
2.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

3.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
4.

Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies.

Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S.

Am J Kidney Dis. 2011 Sep;58(3):374-82. doi: 10.1053/j.ajkd.2011.03.020. Epub 2011 Jun 2. Review.

PMID:
21636193
5.

Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies.

Wang L, Song Y, Manson JE, Pilz S, März W, Michaëlsson K, Lundqvist A, Jassal SK, Barrett-Connor E, Zhang C, Eaton CB, May HT, Anderson JL, Sesso HD.

Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):819-29. doi: 10.1161/CIRCOUTCOMES.112.967604. Epub 2012 Nov 13. Review.

6.

Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies.

Schöttker B, Ball D, Gellert C, Brenner H.

Ageing Res Rev. 2013 Mar;12(2):708-18. doi: 10.1016/j.arr.2012.02.004. Epub 2012 Feb 17. Review.

PMID:
22343489
7.

The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis.

James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV.

Mult Scler. 2013 Oct;19(12):1571-9. doi: 10.1177/1352458513489756. Epub 2013 May 22. Review.

PMID:
23698130
8.

Modifiable factors influencing relapses and disability in multiple sclerosis.

D'hooghe MB, Nagels G, Bissay V, De Keyser J.

Mult Scler. 2010 Jul;16(7):773-85. doi: 10.1177/1352458510367721. Epub 2010 May 18. Review.

PMID:
20483884
9.

Vitamin D status and the risk of multiple sclerosis: a systematic review and meta-analysis.

Duan S, Lv Z, Fan X, Wang L, Han F, Wang H, Bi S.

Neurosci Lett. 2014 Jun 6;570:108-13. doi: 10.1016/j.neulet.2014.04.021. Epub 2014 Apr 24. Review.

PMID:
24769422
10.

Meta-analysis: Serum vitamin D and colorectal adenoma risk.

Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H.

Prev Med. 2011 Jul-Aug;53(1-2):10-6. doi: 10.1016/j.ypmed.2011.05.013. Epub 2011 Jun 13. Review.

PMID:
21672549
11.

Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis.

Li M, Chen P, Li J, Chu R, Xie D, Wang H.

J Clin Endocrinol Metab. 2014 Jul;99(7):2327-36. doi: 10.1210/jc.2013-4320. Epub 2014 Apr 29. Review.

PMID:
24780061
12.

Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.

Simon KC, Munger KL, Ascherio A.

Curr Opin Neurol. 2012 Jun;25(3):246-51. doi: 10.1097/WCO.0b013e3283533a7e. Review.

PMID:
22547098
13.

Vitamin D immunomodulatory potential in multiple sclerosis.

Slavov GS, Trenova AG, Manova MG, Kostadinova II, Vasileva TV, Zahariev ZI.

Folia Med (Plovdiv). 2013 Apr-Jun;55(2):5-9. Review.

PMID:
24191393
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk